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BACKGROUND: Low-dose and long-term administration
of macrolide antibiotics into patients with chronic
airway inflammatory diseases could favorably modify
their clinical conditions. However, the therapeutic
mode of action of macrolides is not well understood.
Free oxygen radicals, including nitric oxide (NO), are
well recognized as the important final effector mole-
cules in the development and the maintenance of
inflammatory diseases.
Purpose: The influence of macrolide antibiotics on
NO generation was examined in vivo.
Methods: Male ICR mice, 5 weeks of age, were orally
administered with either roxithromycin, clarithro-
mycin, azithromycin or josamycin once a day for 2
/4
weeks. The mice were then injected intraperitoneally
with 5.0 mg/kg lipopolysaccharide (LPS) and the
plasma NO level was examined 6 h later.
Results: Although pre-treatment of mice with macro-
lide antibiotics for 2 weeks scarcely affected NO
generation by LPS injection, the administration of
macrolide antibiotics, except for josamycin, for 4
weeks significantly inhibited LPS-induced NO genera-
tion. The data in the present study also showed that
pre-treatment of mice with macrolide antibiotics for
4 weeks significantly suppresses not only production
of pro-inflammatory cytokines interleukin-1b, inter-
leukin-6, and tumor necrosis factor-a, but also in-
ducible nitric oxide synthase mRNA expressions,
which are enhanced by LPS injection.
Conclusion: These results strongly suggest that sup-
pressive activity of macrolide antibiotics on NO
generation in response to LPS stimulation in vivo
may, in part, account for the clinical efficacy of
macrolides on chronic inflammatory diseases.
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Introduction
Low-dose and long-term administration of macrolide
antibiotics, so-called macrolide therapy, is reported
to be effective in the treatment and the management
of chronic inflammatory diseases, such as diffuse
panbronchiolitis and chronic sinusitis.
1,2 It is also
observed that administration of azithromycin (AZM),
a newly developed 15-membered macrolide antibio-
tic, could modify the clinical condition of cystic
fibrosis.
3,4 Although the precise mechanisms of the
macrolide therapy are not well understood, there is
circumstantial evidence that the therapeutic mode of
macrolides is due in part to their anti-inflammatory,
rather than antibacterial, effects.
2,5,6
It is reported that an accumulation of both
neutrophils and macrophages in the airway is an
important feature of the diseases, which is normal-
ized after appropriate macrolide therapies.
7 It is also
recognized that, in response to antigenic stimulation,
these inflammatory cells can secret not only inflam-
matory cytokines, but also free oxygen radicals such
as O2
 and H2O2.
8,9 Our previous work clearly shows
the suppressive activity of macrolide antibiotics on
inflammatory cytokine production from inflammatory
cells, including T cells, mast cells and macrophages
in vitro and in vivo.
5,8,10 However, there is little
information about the influence of macrolide anti-
biotics on free oxygen radical generation from
inflammatory cells.
9
Nitric oxide (NO) is recognized as one of the
important regulators of many cell and tissue func-
tions. It is also accepted NO is produced from various
types of cells and tissues (e.g. skeletal muscle,
epithelium and fibroblasts) in response to inflamma-
tory stimuli.
11 Although NO is generally believed to
be a short-lived gaseous free radical, it reacts
extremely rapidly with superoxide and produces
the very reactive and toxic peroxinitrite, which
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195subsequently decomposes into additional highly
reactive intermediates.
11,12 Clinical evidence has
clearly shown that NO concentration in exhaled air
is increased in patients with airway inflammations,
including rhinitis, as compared with normal sub-
jects.
13,14 Recently, nitrogen derived from oxidants
was found to play a role in airway diseases as one of
the final effector molecules,
15 suggesting the possi-
bility of an important role for peroxynitrite in
inflammatory airway diseases. Recent in vitro studies
clearly showed that macrolide antibiotics, such as
erythromycin and roxithromycin (RXM), significantly
suppress NO generation from both macrophages and
nasal fibroblasts in response to inflammatory sti-
muli.
16,17 These reports may suggest that macrolide
antibiotics exert an attenuating effect on chronic
inflammatory diseases through suppression of NO
generation. However, before drawing the conclusion
that this suppressive activity of macrolide antibiotics
underlies one of the therapeutic modes of action of
agents on the diseases, it is necessary to examine
whether macrolide antibiotics could also suppress
NO generation in vivo. In the present study, there-
fore, we examined the influence of macrolide anti-
biotics on NO generation in vivo using an
experimental mouse model.
Materials and methods
Mouse
Specific pathogen free ICR mice were purchased
from Charles River Japan Inc. (Atsugi, Japan). After
arrival at our university, they were kept in filter (0.2
mm)-barriered cages, and provided with autoclaved
food and tap water ad libitum throughout the
experiments to prevent un-wanted microbiological
infection. The rats were all male and 5 weeks of age
at the start of experiments. All animal experimental
procedures were approved by the Animal Care and
Use Committee of Showa University and were carried
out in accordance with the guidelines of the Physio-
logical Society of Japan.
Antibiotics
RXM was kindly donated by Aventis Pharmaceutical
Co. Ltd (Tokyo, Japan) as a water-insoluble, pre-
servative-free pure powder. This agent was well
mixed with 5% tragacanthogum solution at 20.0
mg/ml and diluted with normal saline to give a
concentration of 2.0 mg/ml. The mice were given 2.5
mg/kg of RXM, one-half of the recommended human
therapeutic dose, once a day for 2/4 weeks via a
stomach tube. Clarithromycin (CAM) was also a gift
from Abott Japan Co. Ltd. (Tokyo, Japan) as a
preservative-free pure powder. CAM, dissolved in
normal saline as in the case of RXM, was orally
administered into mice at a dose of 7.0 mg/kg, one-
half of the recommended human therapeutic dose,
once a day for 4 weeks. Josamycin (JM) was
purchased from SIGMA Chemicals (St Louis, MO,
USA) and dissolved in normal saline as was RXM. JM
was also administered orally into mice at a dose of
20.0 mg/kg, the recommended human therapeutic
dose, once a day for 4 weeks. AZM was extracted
from ZITHROMAC dry syrup (Pfizer Co. Ltd., Tokyo,
Japan) for pediatoric use, which contains 100.0 mg of
AZM, Yellow 5 and sodium lauryl sulfate. AZM was
dissolved by suspending dry syrup in 5.0 ml of
ethanol, and then homogenized with a sonic dis-
membrator for 5 min at 48C, and centrifuged at 5000
rpm for 15 min at 48C. The supernatants were
collected and the ethanol was evaporated. The
resultant powder was dissolved in saline as RXM
administered orally into mice at a dose of 8 mg/kg
once a day for 4 weeks. In all cases, the volume
administered did not exceed 0.2 ml, and control mice
received 5% tragacanthogum solution alone.
Lipopolysaccharide treatment
Mice were injected intraperitoneally with lipopoly-
saccharide (LPS) derived from Escherichia coli
(SIGMA Chemicals) in a volume of 0.5 ml.
Preparation of plasma
Blood (1.0 ml) was obtained from cardiac puncture in
the presence of 0.1 ml of heparin, and then centri-
fuged at 3000 rpm for 10 min at 48C. Plasma was
obtained and stored at /408C until used.
Assay for NO (NO2
/NO3
)
To remove proteins from plasma, samples were
filtered through centrifugal ultrafiltration devices at
5000 x g for 30 min at 48C (Centricon YM-10; cut-off
molecular weight, 10,000; Millipore Corp., Bedford,
MA, USA). The NO levels in samples were examined
by a NO assay kit that contained sufficient reagents
(DojinDo, Co., Ltd, Kumamoto, Japan).
Assay for cytokines
Interleukin (IL)-1b, IL-6 and tumor necrosis factor-a
(TNF-a) levels in plasma were examined using
commercially available mouse cytokine enzyme-
linked immunosorbent assay kits (R & D Corp.,
Minneapolis, MN, USA). The sensitivity of these kits
for IL-1b, IL-6, and TNF-a was 3.0 pg/ml, 7.0 pg/ml,
and 2.0 pg/ml, respectively.
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expression
The lungs were obtained from mice after decapita-
tion, and homogenized with a glass homogenizer at
48C for 60 sec. Poly A
 mRNA was separated from
homogenates with oligo(dT)-coated magnetic mi-
crobeads (Milteny Biotec, Bergische Gladbach, Ger-
many). Inducible nitric oxide synthase (iNOS) mRNA
was examined with mouse iNOS mRNA enzyme-
linked immunosorbent assay test kits (R & D Corp.)
according to the recommended manufacturer’s pro-
tocol.
Statistical analysis
Data were analyzed with analysis of variance fol-
lowed by Fisher’s PLSD test. p B/0.05 was considered
significant.
Results
Influence of macrolide antibiotics on NO
production by LPS stimulation in vivo
The first experiments were undertaken to examine
the time course of NO production after LPS injection.
Plasma was obtained from mice 3, 5, 6, 7, and 8 h
after injection of 5.0 mg/kg of LPS, and NO levels
were examined. As shown in Fig. 1, intraperitoneal
injection of LPS caused a transient increase in NO
levels in plasma. NO levels in plasma gradually
increased, peaked at 6/7 h, and decreased to control
levels by 8 h after LPS injection.
The next experiments were carried out to examine
the optimum concentration of LPS to induce NO
production in mice. Donor mice were given intraper-
itoneal injections of 1.0, 2.5, 5.0, and 6.0 mg/kg of
LPS, and plasma NO levels were examined 5 h later.
The data in Fig. 2 shows that LPS injection of 1.0 mg/
kg caused a significant increase in NO levels in
plasma. NO levels in plasma were further increased
when more than 5.0 mg/kg of LPS was used for
stimulation of NO production.
We then examined the influence of macrolide
antibiotics on NO production in response to LPS
stimulation in vivo. To do this, mice were pre-treated
with 2.5 mg/kg/day of RXM for 2/4 weeks. These
mice received intraperitoneal injections of 5.0 mg/kg
of LPS, and plasma NO levels were examined 5 h
later. Although pre-treatment of mice with RXM for 2
weeks did not affect NO production in response to
LPS stimulation in vivo, pre-treatment for longer
periods (4 weeks) could suppress the ability of
FIG. 1. Time course of NO (NO2
/NO3
) generation after LPS injection in mice. ICR mice were injected intraperitoneally with 5.0
mg/kg of LPS, and plasma NO2
/NO3
 levels were examined at 3, 5, 6, 7, and 8 h after injection. The data are expressed as the
mean (mM) 9 / standard error of ﬁve mice. * Signiﬁcant compared with normal control (0 h).
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further examined whether macrolide antibiotics ex-
cept for RXM could also exert a suppressive effect on
NO production induced by LPS stimulation. As
shown in Fig. 4, AZM and CAM, but not JM,
completely suppressed NO production induced by
FIG. 2. Dose/response proﬁle of NO (NO2
/NO3
) generation by LPS injection in mice. ICR mice were injected intraperitoneally
with various concentrations of LPS, and plasma was obtained 6 h later to assay NO2
/NO3
 levels. The data are expressed as
the mean (mM) 9 / standard error of ﬁve mice. * Signiﬁcant compared with normal control (0 mg/kg); ** signiﬁcant compared
with 2.5 mg/kg of LPS.
FIG. 3. Inﬂuence of RXM on NO (NO2
/NO3
) generation in response to LPS injection. ICR mice were administered orally with
RXM once a day for 2 and 4 weeks at a dose of 2.5 mg/kg of RXM. The mice were then injected intraperitoneally with 5.0 mg/kg
of LPS, and plasma NO2
/NO3
 levels were examined 6 h later. The data are expressed as the mean (mM) 9 / standard error of
ﬁve mice. * Not signiﬁcant compared with LPS alone; ** signiﬁcant compared with LPS alone.
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suppressive activity of AZM and CAM on NO
production was much stronger than that of RXM.
Influence of macrolide antibiotics on pro-
inflammatory cytokine appearance in plasma
after LPS injection
The present experiments were performed to examine
the influence of macrolide antibiotics on pro-inflam-
matory cytokine production by LPS injection. We first
examined the time course of pro-inflammatory cyto-
kine, IL-1b, IL-6 and TNF-a production after LPS
injection. Normal mice were injected intraperitone-
ally with 5.0 mg/kg of LPS, and plasma samples were
obtained 0 (before LPS injection), 1, 2, 3, and 4 h after
LPS injection. As shown in Fig. 5 (upper panels), LPS
injection caused a transient increase in pro-inflam-
matory cytokine levels in plasma; IL-1b and IL-6
levels in plasma peaked at 2 h, and then decreased to
normal levels (before LPS injection) by 4 h. TNF-a
levels in plasma also showed a similar pattern to
those observed in IL-1b and IL-6, peaking 1 h after
LPS injection and then decreasing to normal levels by
3 h. We next examined whether pre-treatment of
mice with macrolide antibiotics could suppress pro-
inflammatory cytokine production induced by LPS
injection. Mice were pre-treated orally either with
RXM, AZM, CAM or with JM once a day for 4 weeks.
They were then injected intraperitoneally with 5.0
mg/kg of LPS, and plasma was obtained 1 h later for
TNF-a assay, and 2 h later for IL-1b and IL-6 assays.
As shown in Fig. 5 (lower panels), macrolide
antibiotics without JM significantly suppress cytokine
levels in plasma.
Influence of macrolide antibiotics on iNOS
mRNA expression in lung after LPS injection
The final experiments were designed to examine the
influence of macrolide antibiotics on iNOS mRNA
expression induced by LPS injection. The data in Fig.
6 clearly show that macrolide antibiotics without JM
significantly suppress iNOS mRNA expression in the
lung, which was increased by LPS injection.
Discussion
Macrolide antibiotics are well known to be effective
against Gram-positive bacteria and are frequently
used in the treatment of upper and lower respiratory
tract infections. Since the initial success of treatment
of diffuse panbronchiolitis with erythromycin, the
most famous 14-membered macrolide antibiotic, for
longer than 3 months was reported by Kudoh et al.,
18
this therapy was used for the treatment and the
management of airway inflammatory diseases, in-
cluding chronic sinusitis with remarkable success.
1,2
Much effort has been made to understand the
mechanisms underlying the clinical efficacy of
macrolides, and has revealed that the anti-inflamma-
tory action of macrolides, but not bactericidal activity,
is responsible for the effectiveness of macrolide
therapy.
5,6,810 However, the precise mechanisms
are not well understood. The present results strongly
suggest that the suppressive activity of macrolide
antibiotics on NO generation in response to LPS
stimulation in vivo may, in part, account for the
clinical efficacy of macrolides on chronic inflamma-
tory diseases. This conclusion may be supported by
FIG. 4. Inﬂuence of several types of macrolide antibiotics on NO (NO2
/NO3
) generation in response to LPS injection.ICR mice
were administered orally with either JM, AZM, or CAM once a day for 4 weeks. The mice were then injected intraperitoneally
with 5.0 mg/kg of LPS, and plasma NO2
/NO3
 levels were examined 6 h later. The data are expressed as the mean (mM) 9 /
standard error of ﬁve mice. * Not signiﬁcant compared with LPS alone.
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but not short-term (2 weeks), administration of 14-
membered macrolide antibiotics (RXM and CAM)
could suppress NO generation in vivo; and (2)
FIG. 5. Inﬂuence of macrolide antibiotics on pro-inﬂammatory production in response to LPS injection. ICR mice were
administered orally with either RXM, CAM, AZM, or JM once a day for 4 weeks. The mice were then injected intraperitoneally
with 5.0 mg/kg of LPS, and plasma cytokine levels were examined. Upper panels, the time course responses of cytokine
productions, expressed as the mean (pg/ml) 9 / standard error of ﬁve mice. *Signiﬁcant as compared with cytokine level before
LPS injection. Lower panels, the inﬂuence of macrolide antibiotics on cytokine productions. IL-1b and IL-6 levels in plasma
were examined 2 h after LPS injection. The TNF-a level in plasma was examined 1 h after LPS injection. Data expressed as the
mean (pg/ml) 9 / standard error of ﬁve mice. *Signiﬁcant as compared with LPS alone; **not signiﬁcant as compared with LPS
alone.
FIG. 6. Inﬂuence of macrolide antibiotics on iNOS mRNA expression in lung tissues. ICR mice were orally administered with
either RXM, AZM, CAM, or JM once a day for 4 weeks. The mice were then injected intraperitoneally with 5.0 mg/kg of LPS,
and lung tissue was obtained 6 h later for mRNA expression. NC, normal control. * Not signiﬁcant compared with normal
controls with LPS injected; ** signiﬁcant compared with normal controls with LPS injected.
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(JM), which is ineffective in clinical treatment,
2 did
not show any suppressive effects on NO generation.
Recent reports clearly showed that long-term use of
the 15-membered macrolide antibiotic (AZM) could
improve lung function in patients with cystic fibrosis,
which is a chronic inflammatory airway disease in
Caucasians.
3,4 These reports, and the present results
showing the suppressive activity of AZM on NO
generation, may also support the conclusion already
described.
NO is generated in response to pro-inflammatory
cytokine stimulations in a number of cell types (e.g.
immune cells and fibroblasts), following induction of
the inducible form of nitric oxide synthase, iNOS.
11,19
Our previous work clearly showed that pre-treatment
of mice with RXM decreases the ability of immune
cells, such as T cells and macrophages, to produce
pro-inflammatory cytokines induced by LPS injection,
when the agent was administered into mice for
longer than 4 weeks.
5,10 From these reports, it is
reasonable to speculate that pre-treatment of mice
with macrolide antibiotics for 4 weeks decreases LPS-
induced pro-inflammatory cytokine production and
results in inhibition of NO generation. This specula-
tion was supported by the present results showing
that pro-inflammatory cytokine levels in plasma
obtained from mice treated with macrolide antibiotics
except for JM was lower than that from non-treated
mice. iNOS, not present in quiescent cells, is often
induced by inflammatory stimulations, and mediates
the high levels of NO generation for long periods,
resulting in tissue injury and mutations in cells.
11,20,21
Recent reports have clearly shown that drugs, such as
rebamipide
22 and thiaton
23, inhibit the ability of iNOS
to produce NO, and result in the prevention of
intestinal damages caused by free radicals including
NO. These reports leave open the question of
whether the suppressive activity of macrolide anti-
biotics used in this study on NO production is due to
its inhibitory action of iNOS generation by iNOS
mRNA, or its suppression of iNOS activity to produce
NO. We then examined iNOS mRNA expression in
lung tissues. The present results clearly show that
long-term administration of macrolide antibiotics
could suppress iNOS mRNA expression, which is
enhanced by LPS stimulation.
Recently, much attention has focused on the
toxicity of iNOS.
1925 Induction of excessive iNOS
produces endothelial cell injury and inhibits cellular
respiration, which can lead to cell dysfunction and
cell death.
19,25 It is also observed that iNOS could
accelerate the production of a large amount of
superoxide, which readily reacts with hydrogen to
form the most toxic molecule, hydroxyl radical.
25 The
present results clearly show the inhibitory effects of
macrolide antibiotics on iNOS mRNA expression,
suggesting that these agents can cause a decrease in
iNOS levels in cytosole and result in both suppression
of superoxide generation and prevention of tissue
injury in airway tracts.
The conclusion restated is as follows. The sup-
pressive effects of macrolide antibiotics, except for
JM, on NO generation from fibroblasts may be one of
the mechanisms leading to the favorable modification
of airway inflammation in the macrolide therapy. This
conclusion may be supported by clinical observations
during the low-dose and long-term administration of
macrolide antibiotics, showing the ineffectiveness of
JM on airway inflammatory diseases.
2
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